Markeder
Markedssiderne
Hvert marked har sin egen side. Den nævner den ansvarlige myndighed, den offentliggjorte holdning og hver kilde med dato og link til den udstedende instans. Sådan kan enhver oplysning kontrolleres ved kilden.
35 markeder, 141 daterede kilder, pr. 20.08.2026.
Retsstilling pr. stof og marked
Dertil kommer en tabel med retsstillingen pr. stof og marked. Den viser, hvad hver myndighed har offentliggjort om hvert stof, med kilden i hver celle.
Sådan bruger vi oversigten
Det er den oversigt, vi selv slår op i, når en køber spørger, om et stof kan leveres til hans marked. Den er offentliggjort, så svaret ligger klar, før du spørger.
Engelske markedssider
De 35 enkelte markedssider er i øjeblikket offentliggjort på engelsk.
Retligt forbehold
Dette er ikke juridisk rådgivning. De fulde leveringsbetingelser fremgår af vores betingelser.
Enquiry
| Market | Code | Sources | Summary |
|---|---|---|---|
| Britain and Ireland2 | |||
| Ireland (EN) | IE | 2 sources | The HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is Englis... |
| United Kingdom (EN) | GB | 7 sources | The United Kingdom prohibits the sale or supply of any unauthorised medicinal product outright under the... |
| German-speaking markets3 | |||
| Austria (EN) | AT | 3 sources | BASG has published a dedicated position holding that a research-use label does not change a peptide's cl... |
| Germany (EN) | DE | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and sets criminal thresholds f... |
| Switzerland (EN) | CH | 5 sources | Swissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agen... |
| Benelux2 | |||
| Belgium (EN) | BE | 3 sources | Belgium applies EU medicines law through the FAGG, which has published a GLP-1 warning. No dedicated pos... |
| Netherlands (EN) | NL | 3 sources | The IGJ and the NVWA assess offerings jointly and have stated their position on research-use framing dir... |
| Nordics5 | |||
| Denmark (EN) | DK | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Research-chemical framing is a... |
| Finland (EN) | FI | 2 sources | Fimea has warned against injectable peptides sold through social media. Semaglutide is a prescription me... |
| Iceland (EN) | IS | 6 sources | Iceland applies the Medicinal Products Act No. 100/2020, administered by the Icelandic Medicines Agency.... |
| Norway (EN) | NO | 8 sources | Norway applies the legemiddelloven and criminalises trade in listed doping substances under the general ... |
| Sweden (EN) | SE | 5 sources | Lakemedelsverket has a published position on Melanotan II, and a government-commissioned report quantifi... |
| Baltics3 | |||
| Estonia (EN) | EE | 2 sources | Ravimiamet published a dated statement in June 2026 addressing internet-sold peptides marketed for resea... |
| Latvia (EN) | LV | 4 sources | The ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No pe... |
| Lithuania (EN) | LT | 4 sources | The VVKT regulates under the Farmacijos istatymas and requires a wholesale distribution licence. No posi... |
| Central and Eastern Europe6 | |||
| Croatia (EN) | HR | 1 sources | HALMED has published a general rule on online medicine sales. No notice naming research-labelled peptide... |
| Czechia (EN) | CZ | 2 sources | SUKL holds that most synthetic peptides meet the functional definition of a medicinal product, so classi... |
| Hungary (EN) | HU | 5 sources | OGYEI regulates medicines under Act XCV of 2005. A case-by-case research permit exists for controlled su... |
| Poland (EN) | PL | 2 sources | GIF and GIS have issued a joint public warning on synthetic peptides offered as chemical reagents. The P... |
| Slovakia (EN) | SK | 3 sources | SUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press release tied to an INTERPOL o... |
| Slovenia (EN) | SI | 2 sources | JAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropi... |
| Southern Europe4 | |||
| France (EN) | FR | 3 sources | ANSM names compounds individually in its public alerts and has issued sanitary-police decisions against ... |
| Italy (EN) | IT | 1 sources | AIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised ... |
| Portugal (EN) | PT | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a rise in illegal online su... |
| Spain (EN) | ES | 2 sources | AEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to verify pharmacies through... |
| Eastern Mediterranean2 | |||
| Greece (EN) | GR | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific compounds. Regulatory att... |
| Turkey (EN) | TR | 6 sources | Turkey applies Law No. 1262 on Pharmaceutical and Medicinal Preparations of 1928 together with the regul... |
| Western Balkans4 | |||
| Albania (EN) | AL | 7 sources | Albania applies Law no. 105/2014 on medicinal products and the pharmaceutical service, as amended, admin... |
| Bosnia and Herzegovina (EN) | BA | 5 sources | Bosnia and Herzegovina applies a single state-level act, the Law on Medicinal Products and Medical Devic... |
| North Macedonia (EN) | MK | 7 sources | North Macedonia applies the Law on Medicines and Medical Devices, published in the official gazette in 2... |
| Serbia (EN) | RS | 5 sources | Serbia applies the Law on Medicines and Medical Devices, published in the official gazette in 2010 and a... |
| Eastern Europe2 | |||
| Moldova (EN) | MD | 6 sources | Moldova replaced its medicines statute in 2025: Law No. 153 of 19 June 2025 was published in the officia... |
| Ukraine (EN) | UA | 6 sources | Ukraine regulates medicines under the Law on Medicinal Products of 4 April 1996, enforced by the State S... |
| South-eastern EU2 | |||
| Bulgaria (EN) | BG | 5 sources | The BDA regulates under the national medicines law and participates in the EU counterfeit-GLP-1 warning ... |
| Romania (EN) | RO | 3 sources | ANMDMR operates under the EU medicines framework and has publicly identified a fraudulent tirzepatide pr... |